Terms: = Head and neck cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
269 results:
1. The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance.
Kilian M; Friedrich MJ; Lu KH; Vonhören D; Jansky S; Michel J; Keib A; Stange S; Hackert N; Kehl N; Hahn M; Habel A; Jung S; Jähne K; Sahm F; Betge J; Cerwenka A; Westermann F; Dreger P; Raab MS; Meindl-Beinker NM; Ebert M; Bunse L; Müller-Tidow C; Schmitt M; Platten M
Sci Immunol; 2024 May; 9(95):eadj7970. PubMed ID: 38701193
[TBL] [Abstract] [Full Text] [Related]
2. Macrophages: plastic participants in the diagnosis and treatment of head and neck squamous cell carcinoma.
Lin C; Chu Y; Zheng Y; Gu S; Hu Y; He J; Shen Z
Front Immunol; 2024; 15():1337129. PubMed ID: 38650924
[TBL] [Abstract] [Full Text] [Related]
3. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted car-NK cells against human esophageal squamous cell carcinoma.
Lin X; Guan T; Xu Y; Li Y; Lin Y; Chen S; Chen Y; Wei X; Li D; Cui Y; Lin Y; Sun P; Guo J; Li C; Gu J; Yang W; Zeng H; Ma C
Front Immunol; 2024; 15():1337489. PubMed ID: 38566988
[TBL] [Abstract] [Full Text] [Related]
5. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.
Maia A; Tarannum M; Lérias JR; Piccinelli S; Borrego LM; Maeurer M; Romee R; Castillo-Martin M
Cells; 2024 Mar; 13(5):. PubMed ID: 38474415
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
Ding C; Dai DY; Luo ZK; Wang GY; Dong Z; Qin GJ; Du XJ; Ma J
Oral Oncol; 2024 Apr; 151():106725. PubMed ID: 38430711
[TBL] [Abstract] [Full Text] [Related]
7. Exploring miR-155-5p and miR-1246 as Diagnostic and Prognostic Markers in Oral Squamous cell carcinoma.
Maheswari R; Urs AB; Kumar P; Koner BC; Guru SA; Rawat G
Mol Biol Rep; 2024 Feb; 51(1):341. PubMed ID: 38400867
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy of MUC1-targeted car-NK cells against human tongue squamous cell carcinoma.
Lin X; Guan T; Li Y; Lin Y; Huang G; Lin Y; Sun P; Li C; Gu J; Zeng H; Ma C
Front Immunol; 2024; 15():1337557. PubMed ID: 38390321
[TBL] [Abstract] [Full Text] [Related]
9. Enhancing car-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment.
Hatae R; Kyewalabye K; Yamamichi A; Chen T; Phyu S; Chuntova P; Nejo T; Levine LS; Spitzer MH; Okada H
JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38386420
[TBL] [Abstract] [Full Text] [Related]
10. Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.
Lee M; Morris LG
Oncotarget; 2024 Jan; 15():36-48. PubMed ID: 38275291
[TBL] [Abstract] [Full Text] [Related]
11. EpCAM-targeting car-T cell immunotherapy is safe and efficacious for epithelial tumors.
Li D; Guo X; Yang K; Yang Y; Zhou W; Huang Y; Liang X; Su J; Jiang L; Li J; Fu M; He H; Yang J; Shi H; Yang H; Tong A; Chen N; Hu J; Xu Q; Wei YQ; Wang W
Sci Adv; 2023 Dec; 9(48):eadg9721. PubMed ID: 38039357
[TBL] [Abstract] [Full Text] [Related]
12. CD44v6 specific car-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
[TBL] [Abstract] [Full Text] [Related]
13. The role of podoplanin inhibitors in controlling oral cancer progression.
Sayuddin ENEN; Taher M; Arzmi MH; Burhanudin NA; Rostam MA
Arch Oral Biol; 2024 Jan; 157():105841. PubMed ID: 37952507
[TBL] [Abstract] [Full Text] [Related]
14. Preoperative and Postoperative C-Reactive Protein to Albumin Ratio (car) as a Prognostic Marker for Survival of Esophageal Squamous Cell carcinoma Patients After Surgery.
Asaka S; Shimakawa T; Nishiguchi R; Yamaguchi K; Murayama M; Usui T; Yokomizo H; Shiozawa S
Anticancer Res; 2023 Nov; 43(11):5139-5147. PubMed ID: 37909952
[TBL] [Abstract] [Full Text] [Related]
15. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract] [Full Text] [Related]
16. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Luke JJ; Patel MR; Blumenschein GR; Hamilton E; Chmielowski B; Ulahannan SV; Connolly RM; Santa-Maria CA; Wang J; Bahadur SW; Weickhardt A; Asch AS; Mallesara G; Clingan P; Dlugosz-Danecka M; Tomaszewska-Kiecana M; Pylypenko H; Hamad N; Kindler HL; Sumrow BJ; Kaminker P; Chen FZ; Zhang X; Shah K; Smith DH; De Costa A; Li J; Li H; Sun J; Moore PA
Nat Med; 2023 Nov; 29(11):2814-2824. PubMed ID: 37857711
[TBL] [Abstract] [Full Text] [Related]
17. CD22 is a potential target of car-NK cell therapy for esophageal squamous cell carcinoma.
Liu T; Dai X; Xu Y; Guan T; Hong L; Zaib T; Zhou Q; Cheng K; Zhou X; Ma C; Sun P
J Transl Med; 2023 Oct; 21(1):710. PubMed ID: 37817249
[TBL] [Abstract] [Full Text] [Related]
18. Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (car-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung cancer (SCLC).
Zhou D; Byers LA; Sable B; Smit MD; Sadraei NH; Dutta S; Upreti VV
J Clin Pharmacol; 2024 Mar; 64(3):362-370. PubMed ID: 37694295
[TBL] [Abstract] [Full Text] [Related]
19. Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to head and neck cancer.
Jacobs MT; Wong P; Zhou AY; Becker-Hapak M; Marin ND; Marsala L; Foster M; Foltz JA; Cubitt CC; Tran J; Russler-Germain DA; Neal C; Kersting-Schadek S; Chang L; Schappe T; Pence P; McClain E; Zevallos JP; Rich JT; Paniello RC; Jackson RS; Pipkorn P; Adkins DR; DeSelm CJ; Berrien-Elliott MM; Puram SV; Fehniger TA
Clin Cancer Res; 2023 Oct; 29(20):4196-4208. PubMed ID: 37556118
[TBL] [Abstract] [Full Text] [Related]
20. Travel-associated cost savings to patients and the health system through provision of specialist head and neck surgery outreach clinics in rural New South Wales, Australia.
Venchiarutti RL; Pearce A; Mathers L; Dawson T; Ch'ng S; Shannon K; Clark JR; Palme CE
Aust J Rural Health; 2023 Oct; 31(5):932-943. PubMed ID: 37501345
[TBL] [Abstract] [Full Text] [Related]
[Next]
